Angiotensin-converting enzyme inhibitor (ACE-I) enalapril’s cardioprotective benefits were examined in a randomized, controlled trial involving 473 patients, 53% of whom were being treated with high doses of anthracyclines for breast cancer. This evidence concerns the gene ACE and breast carcinoma.